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predetermined mark-up schedule and a flat rate for dispensing. These costs were then tabulated and averaged for a 5-year period for each group. The costs were not discounted even though discounting was relevant (the costs were incurred during a 5-year period). The price year was 2000.
Statistical analysis of costs
The costs were treated deterministically. However, a pooled two-sample Student's t-test was undertaken to test the null hypothesis that the mean annual cost of CPT is higher than that of the mean annual cost of IDT. The analysis was conducted using statistical software (Minitab Inc.).
Indirect Costs
The indirect costs were not included.
Currency
Canadian dollars (Can$).
Sensitivity analysis
To investigate the generalisability of the results, a sensitivity analysis was carried out on variables considered to be sensitive. These included the cost of the pump, changes in the pump battery's life, and complications associated with surgery for IDT caused by infection or catheter displacement, occlusion, or fracturing. The authors also looked at the best-and worst-case complication scenarios and their impact on the treatment decision.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total annual costs per patient during the 5-year period were Can$29,410 for patients in group A (IDT) and Can$38,000 for patients in group B (CPT). The mean annual cost was Can$5,882 for group A and Can$7,600 for group B. The costs were compared statistically and a significant difference between the mean treatment costs of IDT and CPT was found, (p=0.028). The costs of adverse effects were included in these results.
Synthesis of costs and benefits
Not relevant as a cost-consequences analysis was carried out. The sensitivity analyses showed that a 50% increase in the pump cost would lead to a 24% increase in the total costs, and thus the recovery period would be lengthened to 33 months. In addition, if technology extended the life expectancy of the pump, a second pump may not be required within the 5-year period. Finally, if the costs of complications were decreased by 50%, the total costs would decrease by 7.9% and the recovery period would be shortened to 26 months. It is difficult to interpret how these findings would affect the treatment decision. The findings of the best-and worse-case scenarios showed that, even in the worst case with high complications, IDT was still the most cost-effective treatment choice.
Although no explicit justification was given for the comparator used, it would appear to represent current practice in the authors' setting. You should decide if the comparator represents current practice in your own setting.
Validity of estimate of measure of effectiveness
The analysis used a randomised controlled trial, which was appropriate for the study question. The study sample was representative of the study population and the patient groups were shown to have been comparable at analysis. Although a randomised controlled trial was conducted and the groups were matched for patient age, gender and the number of operations undergone, to minimise confounding the outcomes were analysed for treatment completers only. Due to the nature of the analysis undertaken, attrition bias cannot be ruled out. In addition, the lack of information on the randomisation and matching procedure suggests that the internal validity of the study may be limited. The authors appear to have been selective in their reporting as they have failed to provide the effectiveness results for group B.
Validity of estimate of measure of benefit
No summary measure of benefit was derived since a cost-consequences analysis was conducted.
Validity of estimate of costs
All the categories of cost relevant to the perspective adopted appear to have been included in the analysis. The costs and the quantities were reported separately, thus enhancing the generalisability of the results to other settings. The unit costs were taken from a variety of sources, all of which were clearly reported. The price year was given as 2000, thus aiding any future reflation exercises. The rate at which Regina General Hospital is reimbursed by the Government of Saskatchewan was used as a proxy for the hospitalisation costs. The authors did not discount either the costs or health benefits, even though this would have been appropriate since the costs were incurred during a 5-year period.
